Pfizer Inc is hoping to release its experimental rheumatoid arthritis drug after successfully completing another stage of a clinical trial.

The trial showed that after six months of use, the drug, tofacitinib, RIFT Platinum significantly reduced the signs and symptoms of RA in patients compared to those who were given a placebo, Reuters reports. rift gold The drug worked to improve physical function at three months and resulted in a greater rate of disease remission at six months. No new safety signals were seen by the trial's completion.

If approved Damien Conover, RIFT Platinum an analyst at Morningstar, expects the drug to generate peak annual sales of about $2 billion.

Although previous trials showed that the drug raised bad cholesterol and liver enzyme levels in some patients, investors are still optimistic that the RA drug will be approved.
Rift Gold However, the potential for additional trials due to the U.S. Food and Drug Administration may slow down the process.

"We're in a climate where the FDA is very risk averse," said. "I think there is a strong likelihood we'll see delays, potentially the need for new trials."

Other RA drugs currently in the market are injectable treatments such as Humira,RIFT Platinum made by Abbott Laboratories, and Amgen Inc's Enbrel.